Results 141 to 150 of about 187,783 (355)
Thoracic Cancer, Volume 13, Issue 24, Page 3496-3503, December 2022., 2022 Patients with T790M‐negative EGFR‐mutant advanced NSCLC received anlotinib plus platinum‐based chemotherapy after resistance to first‐ or second‐generation EGFR TKIs. The maximum tolerated dose (MTD) of anlotinib was 12 mg, and the median PFS was 5.75 (95% CI: 4.37–7.52) months.
Juan Li +7 more
wiley +1 more source
Changes in kidney function in a population with essential hypertension in real life settings [PDF]
, 2017 Introduction. Hypertension has been identified as one of the commonest modifiable determinants for chronic kidney disease progression. A variety of antihypertensive drugs are available and their effect on kidney function has been investigated by a ...
Haidich, Anna-Bettina +6 more
core
Ultracentrifuge and electrophoretic studies on the proteinuria of the new-born calf [PDF]
, 1960 A. E. Pierce, P. Johnson
openalex +1 more source
International Journal of Gynecology &Obstetrics, EarlyView.Abstract Objective To describe the rate of combinations of fetal lies and presentations in twin pregnancies at delivery and to assess the effects of fetal lies and presentations on mode of delivery as well as fetal and maternal birth outcomes. Methods This population‐based cohort study used real‐world data from the Medical Birth Registry of Norway and ...
Meryam Sugulle +4 more
wiley +1 more source
Delayed Onset of Proteinuria in Ageing Hypophysectomized Rats [PDF]
, 1965 Arthur V. Everitt, LEANNA K. DUVALL
openalex +1 more source
The reliability of the Albustix test for proteinuria [PDF]
, 1963 M. R. Wills, G. K. McGowan
openalex +1 more source
iMetaOmics, EarlyView.This study investigates the risk of thrombotic microangiopathy (TMA) induced by vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) inhibitors in cancer therapy. Using data from the FDA Adverse Event Reporting System (FAERS), the WHO Global Database for Adverse Drug Reactions (Vigibase), and The Cancer ...
Aimin Jiang +7 more
wiley +1 more source
Journal of Clinical Laboratory Analysis, EarlyView.Our research is important for identifying the optimal FT3 range to delay the progression of cardiovascular disease in patients with T2DM. These findings provide valuable insights to guide clinicians in preventing and managing cardiovascular disease in this population.
Jinmei Xu +3 more
wiley +1 more source